Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

SelfRugger

2026-02-23 01:18:20

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

Jeff Lewis

Sun, February 22, 2026 at 12:39 AM GMT+9 2 min read

In this article:

IQV

-2.21%

IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 from $265 but still maintained an Overweight rating, updating its estimates after the company’s quarterly results.

On February 10, 2026, IQVIA Holdings Inc. (NYSE:IQV) and the Duke Clinical Research Institute announced a collaboration aimed at advancing clinical research in obesity and related cardiometabolic trials. Chief Medical and Scientific Officer Jeffrey Spaeder said the partnership is designed to “set a new standard for prospective collaboration” between life science service companies and academic research organizations, with a focus on accelerating clinical trial planning and delivery. The companies said the combined capabilities are intended to improve trial efficiency and speed timelines for bringing therapies to patients.

IQVIA reported fourth-quarter revenue of $4.36 billion on February 5, 2026, above the $4.08 billion consensus estimate. CEO Ari Bousbib said the company closed 2025 with strong performance across all segments, delivering near double-digit revenue and EPS growth, along with its strongest quarter of the year in R&DS net bookings. He added that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth across both commercial and clinical businesses, positioning the company for 2026.

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

IQVIA Holdings Inc. (NYSE:IQV) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

Condiciones y Política de privacidad

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.